A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has ...

【导读】胃肠道间质瘤（GIST）在临床上具有异质性，在个体患者中表现出不同程度的疾病侵袭性。团队全面描述了117例GIST队列的基因组和转录组学景观，包括来自105例患者的31例低风险、18例中危、29例高风险、34例转移性和5例新辅助GIST。20 ...

Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

“Our results indicate that the combination of ziftomenib and imatinib acts via a synthetic lethal mechanism through which ziftomenib targets an epigenetic vulnerability of GIST tumors, creating ...

Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models – – Proof-of-concept study of ziftomenib plus ...

11月 3 日，中国科学院上海营养与健康研究所王跃祥团队、华大 基因智惠医学 研究院吴逵团队和上海交通大学附属仁济医院曹晖团队在 Nature Communications 在线发表了题为 Genomic and Transcriptomic Landscape of Human Gastrointestinal Stromal Tumors 的研究 论文 ...

Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase 1a do ...